A non-acetyl cholinesterase inhibitor called memantine is used to treat Alzheimer's disease. The medication was given the go-ahead for sale in Europe in 2002 and by the US Food and Drug Administration (US FDA) in 2003. Since 2015, the medications have been available in generic form. Memantine helps cure mild to severe dementia brought on by Alzheimer's disease. After extended use, the medication may cause Stevens-Johnson syndrome, a severe skin reaction marked by itchy blisters on the skin.